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ABSTRACT 
Calcium channel blockers prevent calcium from entering cells of the heart and blood vessel walls, resulting in lower blood pressure. Calcium 
channel blockers, also called calcium antagonists, relax and widen blood vessels by affecting the muscle cells in the arterial walls. Physico-chemical 
analysis methods are increasingly being introduced into fundamental pharmaceutical research and pharmaceutical analysis practice, taking into 
account their high sensitivity, accuracy, specificity and expressiveness.  
Analytical method development is increasingly being introduced into fundamental pharmaceutical research and pharmaceutical analysis practice, 
taking into account their high sensitivity, accuracy, specificity and expressiveness.  
Search criteria was analytical method development for medicines from group of calcium channel blockers. Literature survey has been done in range 
of years 1990-2018 to make the review updated and comprehensive and to show the new approacheches to the development of the methods of 
analysis of calcium channel blockers. The sources were world recognized journals and key words used as filter were calcium channel blockers, 
amlodipine, nifedipine, verapamil, validation, method development, spectrophotometry, HPLC, UHPLC. Chromatographic methods of analysis 
amongst others have the greatest specificity and objectivity and allow for qualitative and quantitative determination of API in combinated dosage 
forms and biological fluids without prior separation of the components. We can conclude that analysts are constantly working on developing new 
methods of analysis and their optimization in order to save time and consumables, which also ensures the efficiency of the developed method. The 
main disadvantage of the described methods of API analysis can be considered long term from the beginning of chromatography to API release and 
specific solvents used as the mobile phase in HPLC. It is necessary to develop methods and to select such chromatographic conditions that will 
provide high speed and high efficiency at lower pressure of the system. This reduces the amount of used mobile phase, which reduces cost analysis 
accordingly, while at the same time providing the necessary specificity, accuracy and reproducibility of the results of the analysis during quality 
control. Also, the reduction of analysis time is achieved by simplifying the conditions for sample preparation.  
Keywords: Calcium channel blockers, Amlodipine, Nifedipine, Verapamil, Validation 




Calcium channel blockers prevent calcium from entering cells of the 
heart and blood vessel walls, resulting in lower blood pressure. 
Calcium channel blockers, also called calcium antagonists, relax and 
widen blood vessels by affecting the muscle cells in the arterial walls. 
Some calcium channel blockers have the added benefit of slowing 
heart rate, which can further reduce blood pressure, relieve chest 
pain (angina) and control an irregular heartbeat. 
Some calcium channel blockers are available in short-acting and 
long-acting forms. Short-acting medications work quickly, but their 
effects last only a few hours. Long-acting medications are slowly 
released to provide a longer lasting effect [1]. 
Calcium channel blockers were first identified in the lab of German 
pharmacologist Albrecht Fleckenstein beginning in 1964. In 
1021, Avicenna introduced the medicinal use of Taxus 
baccata for phytotherapy in The Canon of Medicine. He named this 
herbal drug "Zarnab" and used it as a cardiac remedy. This was the 
first known use of a calcium channel blocker drug, which were not in 
wide use in the Western world until the 1960s. [2]. 
Physico-chemical analysis methods are increasingly being 
introduced into fundamental pharmaceutical research and 
pharmaceutical analysis practice, taking into account their high 
sensitivity, accuracy, specificity and expressiveness. 
Search criteria was analytical method development for medicines from 
group of calcium channel blockers. Literature survey has been done in 
range of years 1990-2018 to make the review updated and 
comprehensive and to show the new approacheches to the 
development of the methods of analysis calcium channel blockers. The 
sources were world recognized journals and key words used as filter 
were calcium channel blockers, amlodipine, nifedipine, verapamil, 
validation, method development, spectrophotometry, HPLC, UHPLC. 
Methods of analysis of amlidipine 
 
 
Fig. 1: The chemical structures of amlodipine 
 
Amlodipine is a synthetic dihydropyridine and a calcium channel blocker 
with antihypertensive and antianginal properties. Amlodipine inhibits 
the influx of extracellular calcium ions into myocardial and peripheral 
vascular smooth muscle cells, thereby preventing vascular and 
myocardial contraction. Chemical name of amlidipine is 3-~{O}-ethyl 5-
~{O}-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-
1,4-dihydropyridine-3,5-dicarboxylate (fig. 1) [3].  
The State Pharmacopoeia of Ukraine (SPhU) does not have a 
monograph on the substance of amlodipine besylate or on the 
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prepared medical form. However, the United States Pharmacopoeia 
regulates the determination of amlodipine besylate in substances 
and tablets. For identification, UV-spectrophotometry and HPLC/UV 
are proposed. For quantitative determination of amlodipine besylate 
in tablets–HPLC/UV, respectively. Chromatographic conditions for 
the determination of amlodipine besylate, tablets are given in the 
monograph of the United States Pharmacopoeia, which is used the 
chromatographic column of category L1 (fixed phase C18) and 
mobile phase consisting of three components: buffer solution of pH 
3.0 with triethylamine, acetonitrile and methanol. The solvent–
mobile phase, mobile phase rate–1 ml/min, detection wavelength–
237 nm. The proposed method of the United States Pharmacopeia 
requires a long sampling. 
The European Pharmacopeia has a monograph on the substance of 
amlodipine besylate. Identification of amlodipine besylate of the 
European Pharmacopeia regulates the absorption spectro-
photometry in the infrared region and quantitative determination–
HPLC/UV. As a solvent, methanol is used, mobile phase–2.3 g/l of 
ammonium acetate solution P: methanol P (30:70, V/V), mobile 
phase rate–1.5 ml/min, detection wavelength–237 nm. 
Methods of quantitative determination of amlodipine besylate by the 
method of spectrophotometry are described in the scientific 
literature–by products of reaction with various reagents and by their 
own light absorption, kinetic-spectrophotometric method in 
substance and drugs, by the method of inhibition of 
chemiluminescence, by chromatography methods. 
Historical development of methods for the quantitative 
determination of amlodipine besylate in substances and drugs is 
closely related to the development of analytical methods themselves 
and pharmaceutical analysis in general. Nowadays the literature 
contains a large number of scientific papers devoted to the 
quantitative determination of amlodipine besylate and other APIs in 
one medical form, since amlodipine is used in combination with 
different APIs for the treatment of hypertension. Specifically, the 
researchers proposed spectrophotometric methods for the 
determination of amlodipine besylate and atorvastatin in tablets [4-
6], Dake A. S. et al.–spectrophotometric method for the 
determination of amlodipine besylate and enalapril maleate in 
tablets [7], Jain H. K. et al.–spectrophotometric method for the 
determination of amlodipine besylate and lisinopril in tablets [8-10], 
Meyya S. N. et al.–spectrophotometric method for the determination 
of amlodipine besylate and benazepil in medical form [11-15], 
Wankhede S. B. et al.–spectrophotometric method for the 
determination of amlodipine besylate, losartan potassium and 
hydrochlorothiazide in tablets [16]. 
The HPLC method is widely used in the analysis of amlodipine 
besylate both in substance and in mono-and combined drugs. 
Simple, precise, sensitive methods are developed today–liquid 
chromatography, combination of TLC with densitometric 
determination, HPLC/UV, HPLC/DMD, HPLC/MS. For example, 
scientists of the National Pharmaceutical University conducted the 
verification of the method of reverse-phase HPLC with UV-
spectrophotometric detection, which is described in the EPh. 
Validation characteristics such as correctness, linearity, precision, 
specificity, and intra-laboratory precision were studied. This 
HPLC/UV method can be reproduced in the laboratory and does not 
depend on the excipients [17-22]. 
Sivakumar et al. proposed the method of reverse-phase HPLC with UV-
spectrophotometric detection of amlodipine besylate. The method was 
proposed using a mobile phase containing the mixture of methanol, 
acetonitrile and 15 mmol K2NR4
Reverse-phase HPLC with UV-spectrophotometric detection method 
for the determination of amlodipine besylate and enalapril maleate 
in medical form was described by Bharat G. Chaudhari. The 
developed method uses the chromatographic column Phenomenex 
C18, 5 μm, 250 mm×4.6 mm i.d. column and mobile phase–a mixture 
of methanol, acetonitrile, water (40:50:10, V/V/V). The method is 
linear in the range of concentrations of 0.5-6.0 μg/ml and 0.5-8.0 
μg/ml of enalapril maleate and amlodipine besylate, respectively. 
The retention time for enalapril maleate and amlodipine besylate 
was 2.27 and 5.07 min, respectively [28, 29]. 
Sohan S Chitlange et al. developed the method of reverse-phase 
HPLC with UV-spectrophotometric detection of amlodipine and 
metoprolol in tablets using Kromasil C18 column (250 x 4.6 mm, 5 
μm) and mobile phase–a mixture of 0.02 M phosphorus buffer 
solution and acetonitrile (70:30 V/V, pH 3.0), mobile phase rate–1.0 
ml/min, detection wavelength–221 nm [31]. 
The retention time for amlodipine was 2.57 min and metoprolol was 
4.49 min. The linearity of the method was determined in the range of 
concentrations of 10-110 μg/ml of both analytes [32-34]. The same 
authors proposed the method of reverse-phase HPLC with UV-
spectrophotometric detection of the determination of amlodipine 
and valsartan in capsules using the Kromasil C18 column (250 x 4.6 
mm, 5 μm) and mobile phase–a mixture of acetonitrile and 
phosphate buffer solution (0.02M, pH 3.0), (56:44 V/V), mobile 
phase rate–1.0 ml/min, detection wavelength–234 nm. The 
retention time for amlodipine was 3.07 min and valsartan was 6.20 
min. Shi-Ying Dai et al. developed the method of reverse-phase HPLC 
with UV-spectrophotometric detection of the determination of 
amlodipine and ramipril in the presence of impurities in the mode of 
gradient elution [35]. Prathyusha W. et al. proposed the HPLC/UV 
method for the determination of amlodipine besylate, alixerine 
hemifumarate and hydrochlorothiazide in drugs using losartan as 
internal standard. Chromatographic conditions: Inestsil column–
ODS C18 (100x4.6 mm, 5 μm), mobile phase–a mixture of 0.1 M 
ammonia buffer solution and acetonitrile (65:35 V/V), mobile phase 
rate–1.0 ml/min, detection wavelength–232 nm. The retention time 
for amlodipine was 5.22 min, alixerine hemifumarate was 3.90 min, 
and hydrochlorothiazide was 1.91 min [36-49]. 
Shalini Pant et al. described the HPLC/UV method for the 
determination of amlodipine besylate and bisoprolol fumarate in 
drugs using a C18 column (250 x 4.6 mm, 5 μm) and mobile phase–a 
mixture of acetonitrile and phosphate buffer solution (50:50 V/V), 
mobile phase rate–1.0 ml/min, detection wavelength–230 nm. The 
retention time for amlodipine was 6.4 min, bisoprolol was 4.4 min. 
Linearity of the method was studied in the range of concentrations 
of 1.3-10.8 μg/ml [50]. 
Reverse-phase HPLC with UV-spectrophotometric detection method for 
the determination of amlodipine besylate and telmisartan in the medical 
form was described by Kayal SD et al. The proposed method uses the 
chromatography column Prontosil C18, 5 μm, 250 mm × 4.6 mm i.d. 
column and mobile phase–a mixture of methanol, potassium dihydrogen 
phosphate buffer solution pH 4.5 (75:25 V/V), mobile phase rate–1.4 
ml/min, detection wavelength–240 nm. The method is linear in the 
range of concentrations of 2-20 μg/ml and 16-160 μg/ml amlodipine 
and telmisartan, respectively. The retention time for amlodipine and 
telmisartan was 3.12 and 5.80 min, respectively [51-55]. 
Raju et al. described the method of reversed-phase HPLC with UV-
spectrophotometric detection for the determination of amlodipine 
and perindopril in combined medical form using Xterra C18 column 
(100 x 4.6 mm, 5 μm) and mobile phase–a mixture of phosphorus 
buffer soultion and acetonitrile (65:35 V/V), mobile phase rate–0.6 
ml/min, detection wavelength–237 nm. Linearity was studied in the 
range of concentrations of 10-50 μg/ml of amlodipine and 200-1000 
μg/ml of perindopril. The retention time for amlodipine and 
perindopril was 8.51 and 5.28 min, respectively [56-64]. 
 buffer solution (pH 5.33) 
(10:42.08:47.92, V/V/V), mobile phase rate–1.12 ml/min [23, 24]. 
Argekar A. P. et al. proposed the combination of liquid 
chromatography and TLC with densitometric determination of 
amlodipine and atenolol in tablets using a mixture of methylene 
chloride, methanol, ammonia solution (8.8:1.3:0.1, V/V) as mobile 
phase [25-27]. 
The literature describes bioanalytical methods for the quantitative 
determination of amlodipine besylate in plasma. Bhatt J. et al. 
developed the express method for the determination of amlodipine 
in blood plasma using HPLC/MS and HPLC/MS/MS. The proposed 
method uses the chromatographic column Hypersil BDS C18, and 
internal standard–imipramide. The method is linear in the range of 
concentrations of 0.1-10 ng/ml. The total time of chromatography 
was 3.2 min [65]. 
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Alsarra I. A. proposed the bioanalytical method for the determination 
of amlodipine in blood plasma and medical form using the developed 
methodology for the study of pharmacokinetics. The method was 
proposed using C18 Hypersil HyPurity column (3 microm, 3.9 mm id x 
150 mm) and mobile phase containing a mixture of acetonitrile, 
potassium dihydrogen phosphate buffer solution (0.05 M) and acetic 
acid (62:38:0.1 V/V/V), mobile phase rate–1.8 ml/min. LOD of 
amlodipine besylate–1.0 ng/ml, limit of quantitation (LOQ)–10.0 
ng/ml. The developed method was used for the analysis of amlodipine 
tablets and for the study of pharmacokinetics [66]. 
Feng Y. et al. described the HPLC/MS method for the determination 
of amlodipine in blood plasma. After extraction with ethyl acetate 
using the internal standard of nicardin, the chromatographic column 
C18 and mobile phase–a mixture of methanol and 1% acetic acid 
solution (65:35 V/V) were used [67]. 
Zarghi A. et al. developed the bioanalytical method for the 
determination of amlodipine in blood plasma using the described 
methodology for the study of pharmacokinetics. The developed 
procedure uses the chromatographic column Nucleosil C8, 5 μm, 125 
mm × 4.6 mm i.d. column and mobile phase–a mixture of acetonitrile 
and 0.01 M sodium dihydrogenphosphate buffer solution (37:63, 
V/V), mobile phase rate–1.5 ml/min, detection wavelength–239 nm. 
Linearity of the method was studied in the concentration range of 
0.5-16 ng/ml. LOQ of amlodipine besylate–0.2 ng/ml [68]. 
Bahrami G. et al. proposed the express HPLC method for the 
determination of amlodipine in serum with fluorescence detection 
and application of the developed method for pharmacokinetic 
studies. Amlodipine was extracted from the blood serum of ethyl 
acetate. Pre-colon derivatization with 4-chloro-7-nitrobenzofuran 
was carried out. Chromatography was performed using the C18 
column and mobile phase consisting of phosphate buffer solution pH 
2.5 (1 ml/l of triethylamine and methanol), mobile phase rate–2.8 
ml/min. As internal standard, propranolol was used. The method of 
quantitative determination of amlodipine besylate in blood serum 
was linear in the range of concentrations of 0.25-16 ng/ml. LOQ was 
0.25 ng/ml. The developed method found its application for the 
study of bioequivalence of tablets of amlodipine 10 mg [69, 70]. 
Scientists Y. Ma, F. Qin, X. Sun studied the pharmacokinetics of 
amlodipine using UHPLC/MS. Chromatography was performed using 
the chromatographic column ACQUITY UPLC BEH C (18) column (50 
mm x 2.1 mm, id, 1.7 microm) and gradient elution (mobile phase–
water and acetonitrile) with mobile phase rate–0.35 ml/min, 
internal standard–nimodipine The method was linear in the range of 
0.15-16.0 ng/ml with lower limit of quantitation (LLOQ)–0.15 
ng/ml. The described method was used to study pharmacokinetics 
in clinical studies [71, 72]. 
Scientists Q. Yu, Z. Y. Hu, F. Y. Zhu developed HPLC/MS method for 
determination of amlodipine and atorvastatin in blood plasma. The 
method was proposed using a C18 chromatographic column and 
gradient elution of mobile phase containing a 0.1% solution of musk 
acid in water and 0.1% of solution of musk acid in acetonitrile, 
mobile phase rate–0.4 ml/min. The developed method was used for 
the determination of amlodipine and atorvastatin in joint application 
for the treatment of patients with hypertension [73]. 
Wei X. et al. proposed the bioanalytical method for the 
determination of amlodipine and nicardin in blood plasma using a 
monolithic cation exchange column. The developed method was 
linear in the range of concentrations of 0.5-50.0 ng/ml of both 
analytes, correlation coefficient–0.998, LOQ–0.2 ng/ml of 
amlodipine and nicardin [74]. 
Scientists Ramani A. V., Sengupta P., Mullangi R. developed the 
UHPLC/MS method for the determination of amlodipine, simvastatin 
and valsartan in blood plasma with the use of pharmacokinetics. The 
method was proposed using the chromatographic column X-Terra 
C18 column and mobile phase containing a mixture of 0.02 M 
ammonium (pH 4.5) and acetonitrile (20:80 V/V), mobile phase 
rate–0.5 ml/min. The method is linear in the range of 0.5-50 ng/ml 
of valsartan and 0.2-50 ng/ml of amlodipine and simvastatin. The 
correlation coefficient was more than 0.996 for all analytes. The 
developed method was used for pharmacokinetic studies [75-97]. 
Methods of analysis of nifedipine 
 
 
Fig. 2: The chemical structures of nifedipine 
 
Nifedipine is a dihydropyridine calcium channel blocking 
agent. Nifedipine inhibits the transmembrane influx of 
extracellular calcium ions into myocardial and vascular smooth 
muscle cells, causing dilatation of the main coronary and systemic 
arteries and decreasing myocardial contractility. Chemical name of 
nifedipine is dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-
dihydropyridine-3,5-dicarboxylate (fig. 2) [3].  
The State Pharmacopoeia of Ukraine (SPhU) has a monograph on the 
substance of nifedipine. For identification of the substance of 
nifedipine, the SPhU offers the determination of melting point, 
absorption spectrophotometry in the infrared region, TLC (mobile 
phase–ethyl acetate P–cyclohexane (40:60)) and qualitative reaction 
of formation of azo dye after the previous restoration of nitro group to 
amino group, quantitative determination–cerimetry. The United States 
Pharmacopoeia regulates the definition of nifedipine in substances and 
tablets. For identification, the definition of absorption 
spectrophotometry in the infrared region and UV-spectrophotometry 
is proposed. For quantitative determination of nifedipine in tablets–
HPLC/UV method. In accordance with this article, the following 
chromatographic conditions are used: chromatographic column of 
category L1 (with fixed phase C18) with sixe 4.6 mm x 250 mm; 
mobile phase–acetonitrile: methanol: water (25:25:50); solvent–
methanol, wavelength–235 nm, flow rate–1.0 ml/min. 
The European Pharmacopoeia has a monograph on the substance of 
nifedipine. For identification, it is proposed to determine the melting 
point, absorption spectrophotometry in the infrared region, TLC 
(mobile phase–a mixture of ethyl acetate P and cyclohexane P (40:60 
V/V) and qualitative reaction to the primary aromatic amino group–
reaction of formation of azo dye (after preliminary reduction of nitro 
group to amino group). For the quantitative determination of 
nifedipine–method of cerimetry. 
Methods of quantitative determination of nifedipine by methods of 
spectrophotometry and chromatography are described in the 
scientific literature. 
Scientists Sathis Kumar Dinakaran, Babitha Alluri, Koushik Reddy 
Annareddy developed the spectrophotometric method for the 
determination of nifedipine and atorvastatin in substances and 
medical form. For the analysis of nifedipine and atorvastatin, it is 
recommended to use the UV-spectrophotometry method in 
methanol, whose solution has maxima at wavelengths of 237 nm 
(atorvastatin) and 297 nm (nifedipine) [98]. 
Revathi R. et al. proposed spectroscopic determination of nifedipine 
using 40% sodium salicylate solution as hydrotropic solubilizing 
agent. The solutions of complex have absorption maxima at 350 nm 
and are subject to the Bouguer-Lambert-Beer’s law in the range of 
concentrations of 20-100 μg/ml. The proposed method was 
successfully applied to determine APIs in tablets [99, 100]. 
Spectrophotometric determination of nifedipine in drugs, blood 
serum and urine using oxidation-reduction reactions was developed 
by scientists Tulasamma P. and Venkateswarlu P. The proposed 
methods are based on the restoration of the nitro group to the amino 
group. Method A is based on oxidation followed by the combination 
of nifedipine and 3-methyl-2-benzothiazolinone hydrazone in the 
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presence of iron chloride to form a green chromogen color at 685 
nm. Method B is based on the oxidation reaction of nifedipine 
brucine to form a purple chromogen at 546 nm [101]. 
Modi Dixita V., Patel Paresh U. developed the method for 
determination of nifedipine and telmisartan in mixtures. As a 
solvent, methanol was used. The maximum absorption of nifedipine–
235 nm and telmisartan–297 nm. The method was linear in the 
range of 2-20 μg/ml of nifedipine and 1-18 μg/ml of telmisartan. The 
developed method can be used in routine analysis of drugs [102]. 
Scientists AlGhannam S. M., AlOlyan A. M. proposed the spectro-
fluorimetric method for the determination of certain substances from 
the group of 1,4-dihydropyridine, namely nicardipine, nifedipine, 
isradipine in drugs and biological fluids. The method is based on the 
restoration of nicardipine, nifedipine, isradipine from Zn/HCl, and 
fluorescence measurement (λem/λex) at 460/364, 450/393 and 446/360 
nm, respectively. The method was linear in the range of concentrations 
of 0.4-6.0, 0.2-4.0 and 0.1-9.0 μg/ml with LOD 0.0028, 0.017 and 0.016 
μg/ml, respectively. The proposed method was successfully applied for 
the determination of nicardipine, nifedipine, isradipine in medical form 
and biologically advanced liquids (plasma, urine) [103]. 
Scientists Bing L., Hu D. F., Liu F. developed the HPLC/UV method for 
the determination of nifedipine and atenolol in tablets. According to 
the proposed method, the following chromatographic conditions are 
used: chromatographic column Phenomenex-ODS 3 column (250 
mm×4.60 mm, 5 μm); mobile phase –methanol: water: phosphate 
buffer solution; wavelength–240 nm, flow rate–1.0 ml/min. The 
linear dependence is maintained at intervals of 10-250 μg/ml of 
atenolol (correlation coefficient 0.9999) and 4-100 μg/ml of 
nifedipine (correlation coefficient 1.0000) [104]. 
Scientists Cristobal Galan-Rodriguez, Jaime González-Álvarez, 
Màrius Valls-Remolí proposed the UHPLC/UV for the determination 
of nifedipine and its impurities. The chromatography column 
Acquity Shield RP18
Le Guellec C. et al. described the definition of nifedipine in blood 
plasma by the method of gas chromatography. The developed 
method was linear in the concentration range of 0.5-500 ng/ml, 
LOQ–0.5 ng/ml. The method was used to monitor the concentration 
of nifedipine in patients receiving this drug [111]. 
Zendelovska D. et al. proposed the bioanalytical method for 
determination of nifedipine in blood plasma. Chromatography was 
carried out using the mobile phase–a mixture of 0.02 mol/l potassium 
dihydrogen phosphate (pH 4.8) and acetonitrile (42:58, V/V) at 
wavelength 240 nm. Linearity of method was determined in the range of 
concentrations 5.0-200.0 ng/ml, LOQ–5.0 ng/ml [112, 113]. 
Scientists Gurley B. J., Buice R. G., Sidhu P. developed the reverse-phase 
HPLC/UV method for determination of nifedipine in plasma using an 
internal standard of 17-α-ethinylestradiol, mobile phase–a mixture of 
phosphate buffered solution (pH 6.1), methanol, acetonitrile (20:35:45 
V/V/V), chromatography column muBondapak C-18 column at 
wavelength of 235 nm and flow rate of 1.0 ml/min [114, 115]. 
Abou-Auda H. S. et al. described the bioanalytical method for the 
determination of nifedipine in plasma and application of the 
developed method for the study of pharmacokinetics. 
Chromatography was performed using a C18 column, mobile phase–
a mixture of acetonitrile, methanol and water (35:17:48, V/V/V) and 
internal standard–diazepam. The method was linear in the 
concentration range of 10-200 ng/ml and was successfully applied 
for pharmacokinetic studies [116]. 
Scientists Mosab A., Zahaa A., Momir M. proposed the HPLC/UV 
method for determination of nifedipine in plasma of rats to study 
pharmacokinetics and bioequivalence. In this method, the 
chromatographic column Phenomenex Luna-C18 (250 x 4.6 mm, 5 
μm) and mobile phase–a mixture of ammonium, methanol, 
acetonitrile (55: 43: 2, V/V/V), flow rate–0.8 ml/min, wavelength–
235 nm. Linearity of method was determined in the range of 
concentrations 5.00-200 ng/ml, LOQ–6 ng/ml [117]. 
Scientists Yritia M., Parra P., Iglesias E., Barbanoj J. M. developed the 
HPLC/UV method for determination of nifedipine in blood plasma 
using the chromatographic column C18 and mobile phase–a mixture 
of acetonitrile and 13 mmol phosphate buffer solution pH 7 (65:35, 
V/V) at wavelength of 338 nm. LOD–2 ng/ml. The developed method 
was successfully applied for bioequivalence [118]. 
Wang X. D. et al. described the HPLC/MS method for the determination 
of nifedipine and dihydronifedipine in blood plasma, followed by its use 
for the study of clinical interaction of drugs. Nitrendipine was used as an 
internal standard. Chromatographic column–Hypersil BDS C (18) 
column (50 mm x 2.1 mm, i.d., 3 microm). Total chromatography time 
was 2.5 min. The method was linear in the range of concentrations of 
0.5-100 ng/ml of both analytes. LOQ of nifedipine and 
dihydronifedipine–0.5 ng/ml. The developed method was successfully 
applied for pharmacokinetic studies [119]. 
Other scientists also developed the method for determination of 
nifedipine and dihydronifedipine in blood plasma using the 
chromatographic column C18 and mobile phase–a mixture of 
methanol and 50 mmol ammonium acetate solution (50:50, V/V). 
The method was linear in the range of concentrations of 0.5-100 
ng/ml of both analytes [120-121]. 
Methods of analysis of verapamil 
 
 (50×3.0 mm, 1.7 μm) and mobile phase –a 
mixture of 10 mmol ammonium (pH 4.5) and methanol, were used at 
flow rate of 0.5 ml/min. The total time of chromatography was 11 
min. The method was linear in the range of 0.25-1.5 μg/ml of 
nifedipine and its impurities. LOQ–0.05 μg/ml [105, 106]. 
Rosseel M. T. et al. developed the method for determination of 
nifedipine in blood plasma using capillary gas chromatography with 
nitrogen detection. Nifedipine was extracted from plasma with 
toluene. Nitrendipine was used as an internal standard. The method 
was linear in the range of 2-300 ng/ml [107]. 
Scientists Soons P. A., Schellens J. H., Roosemalen M. C., Breimer D. D. 
described the analysis of nifedipine and its pyridine metabolite of 
dihydronifedipine in blood plasma using the method of reverse-
phase HPLC/UV. The published method in 1991 was observational 
and of recommendatory nature [108]. 
Guo Y. et al. proposed the bioanalytical method for the 
determination of nifedipine in plasma and its application for the 
study of bioequivalence. HPLC/MS method for the determination of 
nifedipine in blood plasma was developed. Nifedipine was extracted 
with diethyl ether, dimethoxane was used as an internal standard. 
The chromatography column BDS C (18) and mobile phase–a 
mixture of methanol and water (66:34, V/V) were used. Researches 
on the study of bioequivalence were conducted using the developed 
method of 20 volunteers [109]. 
Wang D., Jiang K., Yang Sh. developed the bioanalytical method for the 
determination of nifedipine in blood plasma by the method of 
UHPLC/MS using the developed methodology for the study of 
pharmacokinetics. The chromatographic determination was performed 
using the chromatography column UPLC™ BEH C (18) column and 
mobile phase–mixture of acetonitrile and 10 mmol/l of ammonium 
acetate solution (75:25, V/V) at flow rate of 0.2 ml/min. The method was 
linear in the range of concentrations of 0.104-52.0 ng/ml, LOQ–0.104 
ng/ml. The method was fully validated and successfully applied to study 
the pharmacokinetics of nifedipine tablets [110]. 
 
Fig. 3: The chemical structures of verapamil 
 
Verapamil is a phenylalkylamine calcium channel blocking 
agent. Verapamil inhibits the transmembrane influx of 
extracellular calcium ions into myocardial and vascular smooth muscle 
cells, causing dilatation of the main coronary and systemic arteries and 
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decreasing myocardial contractility. Chemical name of verapamil is 2-
(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-
amino]-2-propan-2-ylpentanenitrile (fig. 3) [3].  
The State Pharmacopoeia of Ukraine (SPhU) has a monograph on the 
substance of verapamil hydrochloride and on verapamil hydrochloride 
tablets. To identify the substance of verapamil hydrochloride, SPhU 
offers UV-spectrophotometry, absorption spectrophotometry in the 
infrared region, TLC (mobile phase–diethylamine P-cyclohexane 
(15:85)), quantitative determination–alkalimetry, potentiometric 
titration. For identification of verapamil hydrochloride in tablets, SPhU 
proposes UV-spectrophotometry, HPLC/UV (mobile phase–a mixture 
of heptylamine PN
Nafisur Rahman et al. described two spectrophotometric methods 
for the determination of verapamil hydrochloride in drugs. Method 
A is based on the oxidation of verapamil potassium hydrochloride 
with metaperiodate in environment of sulphate acid to the 
formation of colored reaction product having a maximum absorption 
at 425 nm and subject to the Bouguer-Lambert-Beer’s Law in the 
range of 12.5-187.5 μg/ml. Method B is based on the formation of 
colored reaction product with tropaeolin 00 at pH 4.0, which is 
excreted by chloroform, has a maximum absorption at 400 nm and is 
subject to the Bouguer-Lambert-Beer’s law in the range of 2.0-30.0 
μg/ml. Both methods have found their application in the analysis of 
drugs containing verapamil hydrochloride [125-130]. 
Ivanova V. et al. developed the HPLC/UV method for determination 
of verapamil in blood plasma using the chromatographic column 
Lichrospher 60 RP-select B column (250 mm × 4 mm ID, 5 μm) and 
mobile phase–a mixture of 40% acetonitrile and 0.025 mol/l of 
potassium dihydrogenphosphate pH 2.5, flow rate–1 ml/min, 
detection wavelength–200 nm. The method was linear in the range 
of 10-500 ng/ml. The developed method was successfully applied 
for routine analysis of verapamil in blood plasma [131-133]. 
Sawicki W. proposed the validated method for determination of 
verapamil and its metabolite norverpamil in blood plasma. LOD of 
verapamil is 0.924 ng/ml, LOQ–3.080 ng/ml. LOD of 
norvermapamil–0.030 ng/ml, LOQ–1.001 ng/ml. The total time of 
chromatography is 8 min, which makes it possible to make 30-40 
manual analyses per day (without autosampler). The developed 
method was successfully applied for carrying out of pharmacokinetic 
studies and researches on studying bioequivalence of drugs 
containing verapamil [134, 135]. 
–acetic acid of ice P–acetonetrile P–solution of 1.36 
g/l of sodium acetate P (1:4.7:58:1.37)), qualitative reaction to 
chlorides. For quantitative determination of verapamil hydrochloride 
in tablets–UV-spectrophotometry.  
The United States Pharmacopoeia regulates the definition of 
verapamil hydrochloride in substance, tablets and injection solution. 
In order to identify verapamil hydrochloride in the substance, 
determination is made by absorption spectrophotometry in the 
infrared region, HPLC/UV (mobile phase–analogous to SPhU), 
qualitative reaction to chlorides, for quantitative determination–
acidimetry in non-aqueous medium. For the identification of 
verapamil hydrochloride in tablets, the United States Pharmacopoeia 
offers the absorption spectrophotometer method in the infrared 
area and HPLC/UV. The drug Verapamil hydrochloride, tablets are 
described in the monograph of the United States Pharmacopoeia. 
According to this article, the HPLC/UV is regulated by the following 
chromatographic conditions: chromatographic column of category 
L1 (fixed phase C18) size 4.6 mm x 125 or 150 mm; mobile phase–
acetonitrile: 2-aminoheptane: solution A (0.015 M solution of 
sodium acetate containing 33 ml/l of acetic acid) in ratio (30:0.5:70); 
wavelength–278 nm, flow rate–0.9 ml/min. 
The European Pharmacopoeia [3] suggests identifying verapamil 
hydrochloride UV-spectrophotometry substance, absorption 
spectrophotometry in the infrared region, TLC (mobile phase–
diethylamine P–cyclohexane (15:85)) and qualitative reaction to 
chlorides, quantitative determination–alkalimetry potentiometric 
titration.  
Methods of quantitative determination of verapamil hydrochloride 
by spectrophotometry, electrochemical method and chromate-
graphy methods are described in the scientific literature. 
Salh D. M. proposed spectrophotometric determination of verapamil in 
drugs using bromotymol blue. The method is based on the reaction of 
complex formation. The reaction product was extracted with 
tetrachloromethane and the optical density was measured at 420 nm. 
The developed method was completely validated. Coefficient of co-
correlation–0.9951, LOQ–0.009253 μg/ml. The method was 
successfully applied for the analysis of medical form containing 
verapamil hydrochloride (tablets, capsules, ampoules) [122]. 
Scientists Rahman N., Hoda M. N. developed the spectrophotometric 
method for the determination of verapamil hydrochloride in drugs 
using chloramine-T. The method is based on the oxidation reaction 
of verapamil with chloramine-T in acidic environment. The solutions 
of the complex are yellow in color and have absorption maxima at 
425 nm and are subject to the Bouguer-Lambert-Beer’s law in the 
range of concentrations of 0-340 μg/ml. The proposed method was 
successfully applied to determine verapamil hydrochloride in 
medical form [123]. 
Scientists Nafisur Rahman and Syed Najmul Hejaz Azmi proposed 
the spectrophotometric method of verapamil hydrochloride in drugs 
using N-bromosicinamide. The method is based on the oxidation of 
verapamil hydrochloride by N-bromosicinamide in chlorinated acid 
environment at room temperature to give a yellow colored product 
having maximum absorption at 415 nm and subject to the Bouguer-
Lambert-Beer’s law for the concentration range 10.0-200.0 μg/ml. 
The developed method was successfully applied for the 
determination of verapamil hydrochloride in the drug [124]. 
Scientists Stagni G. and Gillespie W. R. described the method for the 
determination of verapamil and its norverapamil metabolite in 
blood plasma. Norverapamil is rapidly acetylated to N-
acetylnorverapamil using 2% butanol in hexane. Verapamil and N-
acetylnorverapamil are separated by α-glycoprotein chiral column 
by mobile phase–a mixture of phosphate buffered solution (0.01 M, 
pH 6.65) and acetonitrile. The wavelengths of the fluorescence 
detector were set at 227 nm for excitation and 308 nm for radiation. 
The method was linear in the range of concentrations of 3-200 
ng/ml of verapamil and 2-100 ng/ml of norverapamil. LOD of 
verapamil was 3 ng/ml and norverapamil–2 ng/ml. The developed 
method was used to study pharmacodynamics [136]. 
Jhee OH et al. developed the bioanalytical method for determining 
verapamil in plasma of rats using mobile phase A (50 mmol 
ammonium phosphate, pH 4.5) and mobile phase B (50 mmol 
ammonium phosphate: acetonitrile, 70:30 v/v). Analysis of 
verapamil and internal standard of propranolol were performed by 
direct introduction of rat plasma into the system and eluted, 
respectively, 22 min (verapamil) and 12 min (propranolol) at mobile 
phase A of 0.5 ml/min and mobile phase B of 0.15 ml/min. The 
method was validated. The correlation coefficient was 0.9997. The 
method was linear in the range of 0.01 to 2.50 μg/ml. LOD–0.01 
μg/ml, LOQ–0.025 μg/ml. The developed method was successfully 
used for the study of pharmacokinetics [137, 138]. 
The method of reverse HPLC/UV determination of verapamil in 
blood plasma was developed by Muscara M. N. and de-Nucci G. 
Flecainide was used as internal standard. The method was 
completely validated and used for pharmacokinetic studies [139]. 
Scientists Lau-Cam C. A. and Piemontese D. proposed the HPLC/UV 
method for determining verapamil in plasma of rats using 
dextromethorphan as an internal standard and mobile phase–a 
mixture of methanol, acetonitrile, triethylamine acetate buffer 
solution (10:30:60 V/V/V/) with detection wavelength of 235 nm, 
flow rate of 1.5 ml/min. The method was linear in the concentration 
range of 0.5-10 μg/ml (correlation coefficient–0.9999). LOD–0.1 
μg/ml. The method was used to monitor the concentration of 
verapamil in the plasma of rats receiving this drug through various 
routes of administration [140]. 
Scientists Hedeland M., Fredriksson E., Lennernäs H., Bondesson U. 
described the bioanalytical method for the determination of 
verapamil enantiomers and their N-dimethylated metabolite in 
blood plasma using HPLC/MS. The mobile phase–a mixture of 85% 
aqueous solution of ammonium acetate pH 7.4 and a 15% solution of 
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acetonitrile, flow rate–0.6 ml/min. The developed method was 
successfully applied for the study of in vivo intestinal permeability 
[141-144]. 
CONCLUSION  
From the above-mentioned, we can conclude that analysts are 
constantly working on developing new methods of analysis and their 
optimization in order to save time and consumables, which also 
ensures the efficiency of the developed method. The main 
disadvantage of the described methods of API analysis can be 
considered long term from the beginning of chromatography to API 
release and specific solvents used as the mobile phase in HPLC. In 
our opinion, it is necessary to develop methods and to select such 
chromatographic conditions that will provide high speed and high 
efficiency at lower pressure of the system. This reduces the amount 
of used mobile phase, which reduces cost analysis accordingly, while 
at the same time providing the necessary specificity, accuracy and 
reproducibility of the results of the analysis during quality control. 
Also, the reduction of analysis time is achieved by simplifying the 
conditions for sample preparation.  
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